x

Sciences

Gilead Sciences Buying Immunomedics in $21 Billion Deal

September 14, 2020

NEW YORK — Shares of the cancer drug specialist Immunomedics more than doubled before the market opened Monday, a day after its sale to Gilead Sciences for $21 billion was announced. 

Gilead said on Sunday that it will pay $88 per share in cash as it seeks to broaden its cancer treatments portfolio. Immunomedics' drug Trodelvy was granted accelerated approval by the U.S. Food and Drug Administration in April for the treatment of adult patients with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease. The drug is also being studied for bladder cancer, lung cancer and other solid tumor types.

The deal is expected to close in the fourth quarter. 

Shares of Immunomedics, based in New Jersey, jumped to $87.14 in premarket trading, while share of California's Gilead declined slightly. 

RELATED

NEW YORK — Buzz Aldrin's jacket worn on his historic first mission to the moon's surface in 1969 has been auctioned off to a bidder for nearly $2.

Top Stories

Columnists

A pregnant woman was driving in the HOV lane near Dallas.

General News

FALMOUTH, MA – The police in Falmouth have identified the victim in an accident involving a car plunging into the ocean on February 20, NBC10 Boston reported.

General News

NEW YORK – Meropi Kyriacou, the new Principal of The Cathedral School in Manhattan, was honored as The National Herald’s Educator of the Year.

Video

Greek-American Cornell Student Rescues Man on Subway Tracks in the Bronx

NEW YORK – Greek-American Cornell University senior Bryce Demopoulos rescued a man who had fallen on the subway tracks at the Third Avenue-138 Street station on the No.

Enter your email address to subscribe

Provide your email address to subscribe. For e.g. abc@xyz.com

You may unsubscribe at any time using the link in our newsletter.